Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 11/20 | 0.49 |
| ▸ | JAK2 | O60674 | 10/20 | 0.49 |
| ▸ | JAK3 | P52333 | 10/20 | 0.49 |
| ▸ | TYK2 | P29597 | 5/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10099359 | 0.93 | JAK2 (0.56) | JAK1JAK2JAK3TYK2 | |
| Trifluoroacetic Acid SCHEMBL3319468 | 0.83 | JAK1 (0.45) | JAK1JAK2JAK3TYK2CHRM2 | |
| Trifluoroacetic Acid SCHEMBL3313371 | 0.83 | JAK1 (0.45) | JAK1JAK2JAK3TYK2CHRM2 | |
| SCHEMBL566555 | 0.79 | JAK1 (0.74) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL565627 | 0.79 | JAK1 (0.74) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL13398079 | 0.76 | JAK1 (0.49) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL13398151 | 0.75 | JAK2 (0.49) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL28887766 | 0.74 | JAK2 (0.48) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL10099452 | 0.74 | JAK2 (0.51) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL14697497 | 0.72 | JAK1 (0.75) | JAK1JAK2JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | JAK1 2/4885JAK2 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.